Modified GAP index by including serum KL-6 to assess risk of disease progression in patients with interstitial lung diseases (ILD): preliminary results from the VAMOS study

ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly

“…Therefore, finding biomarkers that identify patients at higher risk of progressive fibrosis is a huge unmet need. Circulating pneumoproteins like KL-6 seem to be promising in stratifying ILD patients at risk of developing progression at 1 year, according to the preliminary results of the multicentre international VAMOS study [ 15 ]. Easily available peripheral monocytes have also been investigated in a subgroup analysis of the INBUILD trial and show a good correlation with survival and disease progression [ 16 ].…”